Recommendation against PSA test goes too far: expert

October 12, 2011 By Caroline Arbanas

(Medical Xpress) -- A draft recommendation by the U.S. Preventive Services Task Force calling for an end to routine PSA testing for healthy men age 50 and older goes too far, says a prostate cancer expert at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis.

“Mass is not the way to go,” says Gerald Andriole, MD, chief of urologic surgery, who acknowledges that widespread testing has lead many men with slow-growing tumors to be over diagnosed and over treated with aggressive therapies. “We have to take a more nuanced approach to determine which men should be screened in the first place, how frequently they should be tested, and whether their cancer warrants therapy.”

In recommending against routine PSA screening, the task force says that the test does not save lives and, when positive, often leads to invasive biopsies and treatments such as surgery or radiation therapy, with side effects that can include incontinence and impotence.

But Andriole, who also is the principal investigator of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial, argues that it would be a mistake to universally dismiss the PSA test. Rather, he says the decision to screen should be left up to patients and their doctors, who should take into consideration a man’s overall health, age and other risk factors.

Discouraging men with a of dying from – particularly African-Americans and those with a family history of prostate cancer – from getting a PSA test would be misguided, he adds. 

For men who choose to have a PSA test, Andriole urges caution if the test is abnormal. Doctors, he says, often do not need to rush to perform biopsies or recommend aggressive treatments because most prostate tumors grow slowly. In many cases, “active surveillance” may be practical, which involves periodic PSA tests and biopsies to monitor tumor growth rather than opting for immediate aggressive treatment.

Ending PSA screening all together would mean a return to the “pre-PSA” era when about a third of prostate cancers were advanced and incurable at the time of diagnosis.

Preliminary results of the PLCO trial, published in 2009 in the New England Journal of Medicine, indicated that routine PSA screening does not reduce deaths from prostate cancer among men ages 55-74 who had been followed for up to 10 years.

But Andriole says that a close look at younger, healthy men in the study showed an improvement in prostate cancer mortality among those who had PSA tests and digital rectal exams. With longer follow-up, there may be additional benefit to screening for younger men and men who are known to have a high risk of dying from the disease. Updated results of the study are expected to be published later this year.

“Routine annual screening is not necessary for most men,” Andriole says. “But men with a high risk of dying from prostate cancer – particularly African-Americans and those with a family history of prostate cancer – should still be screened.”

Prostate cancer is the second most common cancer among men, after skin cancer. In 2010, nearly 220,000 U.S. received a diagnosis of prostate cancer and an estimated 32,050 died of the disease.

Explore further: New prostate cancer test gives more accurate diagnosis

Related Stories

New prostate cancer test gives more accurate diagnosis

April 6, 2011
In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

tadchem
not rated yet Oct 12, 2011
"has lead many men" or "has led many men"?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.